A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2012 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
- 30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History